Meeting
2023 ASCO Genitourinary Cancers Symposium
Dosing, safety, and pharmacokinetics (PK) of combination therapy with darolutamide (DARO), androgen-deprivation therapy (ADT), and docetaxel (DOC) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) in the ARASENS study.
Authors
Arash Rezazadeh
University of California Irvine Medical Center, Orange, CA
Arash Rezazadeh , Bertrand F. Tombal , Maha H. A. Hussain , Fred Saad , Karim Fizazi , Cora N. Sternberg , E. David Crawford , Shivani Kapur , Weijiang Zhang , Bart Ploeger , Rui Li , Iris Kuss , Carsten Zieschang , Sabine Wittemer-Rump , Matthew Raymond Smith
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT02799602
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 148)
DOI
10.1200/JCO.2023.41.6_suppl.148
Abstract #
148
Poster Bd #
E8
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Overall survival with darolutamide vs placebo in combination with androgen-deprivation therapy (ADT) and docetaxel: A sensitivity analysis from ARASENS accounting for subsequent therapy.
First Author: Neal D. Shore
Poster
2024 ASCO Genitourinary Cancers Symposium
A systematic review: Are the findings of indirect treatment comparisons (ITCs) in metastatic hormone-sensitive prostate cancer (mHSPC) consistent?
First Author: Neal D. Shore
Poster
2023 ASCO Annual Meeting
Open-label study of darolutamide plus androgen-deprivation therapy (ADT) vs ADT in metastatic hormone-sensitive prostate cancer using an external control arm (ARASEC).
First Author: Neal D. Shore
Poster
2023 ASCO Genitourinary Cancers Symposium
Darolutamide plus androgen-deprivation therapy (ADT) versus ADT in metastatic hormone-sensitive prostate cancer: Open-label single-arm study with an external control arm (ARASEC).
First Author: Neal D. Shore